Aradigm Corp fka ARDMQ

[rikic]

Key Investment Highlights

* Aradigm believes the NCFBE indication for Linhaliq exceed $500MM of sales by 2021.
Ladenburhg analysts project $1B sales by 2022, Nektar projected $750 milion for their NCFBE product with Bayer

* US Orphan Drug Designation with no existing approved therapies

* QIDP Designation and Fast Track received
FDA priority review accompanies QIDP designation

* Strong IP protection to 2031
8 patents issued in US; 41 issued patents in 37 countries outside the US

* Important objectives achieved in Phase 3
Prevention and reduction in frequency of pulmonary exacerbations
High persistent drug contrentrations in sputum, low in blood
Sustained powerful antipseudomonal activity even for patients with resistant isolates
Good safety and tolerability

* Commercial Launch in US expected in Q2'2018
EU approval expected Q4'18/Q1'19

* Sole competitor: Bayer's twice dily, dry powder inhaled ciprofloxacin

* Linhaliq is administered once daily:
Active in biofilms, uptake by macrophages